SpePharm prevails in US lawsuit with Eisai

9 September 2019

The US District Court for the District of Delaware ruled on September 4, 2019, in favor of SpePharm in its proceeding against Japan’s Eisai (TYO: 4523), upholding SpePharm's licensed rights for Salagen (pilocarpine hydrochloride) through April 2026.

Judge Richard Andrews upheld independent Dutch pharma firm Norgine subsidiary SpePharm's position, finding that SpePharm properly exercised its option to extend its license agreement in 49 countries.

Eisai, whose shares were up 1.2% at 5,350 yen following the announcement today, purported to give notice of its intent to terminate SpePharm AG's exclusive licensed rights for Salagen, a drug used to treat dry mouth caused by radiation therapy for head and neck cancer and to treat dry mouth and dry eyes in individuals with Sjögren's syndrome, and had entered into an agreement to sell global rights to Salagen to Advanz Pharma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK